A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients

Results from a real-world study in Denmark of patients with HER2-positive metastatic breast cancer previously treated with T-DM1 and currently in third-line or later therapy show that this patient population were treated with various anti-cancer agents, including chemotherapy alone or in combination with HER2-directed therapy, HER2-directed therapy alone, endocrine therapy, experimental treatment, and no treatment. The authors noted that these patients did not have access to newer therapies such as tucatinib and T-DXd at the time of study.